Deirdre Fuller, Oncology Roundtable
CMS’s physician supervision requirements continue to be an area of uncertainty and confusion for many of our members. Here, we have compiled the most up-to-date information on physician supervision for chemotherapy and radiation therapy.
What you need to know about Medicare’s physician supervision requirements
CMS will implement its proposed cuts – with some modifications - to payment for IMRT and SBRT treatment delivery in the freestanding setting.
Last night, CMS issued the final 2013 Hospital Outpatient Prospective Payment System (HOPPS) and the Medicare Physician Fee Schedule (MPFS). The Oncology Roundtable team is currently combing through the regulations, and we will be publishing our analysis over the next several weeks.
CMS Issues Final 2013 HOPPS and MPFS
In case you missed it, our colleagues at Technology Insights posted a new article on their blog this week examing the proliferation of multiple proton therapy providers in single markets.
View their analysis of the changing dynamics of proton patient capture and the potential effects of proton market proliferation on provider institutions included below to learn more.
Chris Pericak and Dave Gaffin, Technology Insights
A local news outlet in West Sussex, UK, recently released an article titled "New Factory to Produce Proton Therapy Systems", conjuring images of factory workers piecing widgets together in a systematic fashion that would make Henry Ford proud.
A closer read, however, reveals that the article is referring to UK-based Tesla Engineering, which makes superconducting magnets that play a role in bringing new small-scale proton therapy models to market. The construction of this new factory reflects a proton therapy supply chain that is readying itself for market proliferation of this technology.
In case you missed it: Proton therapy on an assembly line?